AmpliPhi Biosciences Corporation (APHB) and Cidara Therapeutics Inc. (NASDAQ:CDTX) Contrasting side by side

AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) and Cidara Therapeutics Inc. (NASDAQ:CDTX) compete with each other in the Biotechnology sector. We will analyze and contrast their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AmpliPhi Biosciences Corporation N/A 395.60 10.14M -0.76 0.00
Cidara Therapeutics Inc. N/A 0.00 70.43M -3.11 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for AmpliPhi Biosciences Corporation and Cidara Therapeutics Inc.


Table 2 demonstrates the net margins, return on assets and return on equity of AmpliPhi Biosciences Corporation and Cidara Therapeutics Inc.

Net Margins Return on Equity Return on Assets
AmpliPhi Biosciences Corporation 0.00% -118.6% -84.7%
Cidara Therapeutics Inc. 0.00% -107.2% -80.7%

Risk and Volatility

AmpliPhi Biosciences Corporation has a 2.21 beta, while its volatility is 121.00% which is more volatile than S&P 500. Cidara Therapeutics Inc. has a 1.78 beta and it is 78.00% more volatile than S&P 500.


The Current Ratio and Quick Ratio of AmpliPhi Biosciences Corporation are 2.1 and 2.1 respectively. Its competitor Cidara Therapeutics Inc.’s Current Ratio is 6.8 and its Quick Ratio is 6.8. Cidara Therapeutics Inc. can pay off short and long-term obligations better than AmpliPhi Biosciences Corporation.

Insider and Institutional Ownership

Institutional investors held 5.7% of AmpliPhi Biosciences Corporation shares and 76% of Cidara Therapeutics Inc. shares. Insiders held 1.28% of AmpliPhi Biosciences Corporation shares. Competitively, Cidara Therapeutics Inc. has 2.06% of it’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AmpliPhi Biosciences Corporation -21.59% -27.25% -78.61% -82.93% -79.24% -79.04%
Cidara Therapeutics Inc. -15.38% -26.32% -25.78% -41.33% -61.01% -54.71%

For the past year AmpliPhi Biosciences Corporation’s stock price has bigger decline than Cidara Therapeutics Inc.


Cidara Therapeutics Inc. beats AmpliPhi Biosciences Corporation on 4 of the 7 factors.

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. It is also developing targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. The company has reported results from two Phase I clinical trials of AB-SA01 for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients, as well as evaluating the safety of AB-SA01 when administered topically to the intact skin of healthy adults. Its pipeline also includes AB-PA01 for the treatment of pseudomonas aeruginosa lung infections in cystic fibrosis and chronic rhinosinusitis patients. AmpliPhi Biosciences Corporation has a research collaboration agreement with Royal Brompton Hospital; a license agreement with University of Leicester to develop a phage therapy that targets and kills various clinically relevant toxin types of C. difficile; a cooperative research and development agreement with the U.S. Army Medical Research and Materiel Command and the Walter Reed Army Institute of Research to develop and commercialize bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and a clinical trial agreement with the University of Adelaide. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of various diseases. Its lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious, invasive fungal infections. The company also develops CD201, a novel bispecific antimicrobial immunotherapy for the treatment of multidrug-resistant gram-negative bacterial infections, including those caused by pathogens harboring the mcr-1 plasmid. In addition, it develops a proprietary immunotherapy technology platform Cloudbreak, which is designed to create compounds that direct immune system to attack and eliminate bacterial, fungal or viral pathogens. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.